LM-302 plus gemcitabine for advanced pancreatic cancer with CLDN18.2
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug, LM-302, combined with gemcitabine for people with a specific type of advanced pancreatic cancer that has not responded to or stopped working on first-line treatment. The goal is to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have advanced pancreatic cancer (pancreatic ductal adenocarcinoma) that cannot be surgically removed
- Your cancer must have gotten worse or you could not tolerate standard first-line chemotherapy
- Your tumor must have a specific protein (CLDN18.2) in at least half of the cells
- You cannot have had gemcitabine or nab-paclitaxel before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (FG-M108) combined with standard chemotherapy, compared to chemotherapy alone, for people with advanced pancreatic cancer that has not been treated before. It is for those whose tumors have a specific protein (Claudin18.2) that the drug is designed to attack.
This trial tests a new drug called ANO31905 added to standard chemotherapy for people with advanced pancreatic cancer that has a specific protein called CLDN18.2 on its cells. The study aims to see if the combination works better than chemo alone.
This trial studies a chemotherapy combination (albumin-bound paclitaxel and gemcitabine) as first treatment for pancreatic cancer that cannot be removed by surgery. It aims to improve outcomes by testing how well this treatment works in people with locally advanced or metastatic disease.
This trial tests a new drug called MRG003 combined with gemcitabine for people with advanced pancreatic cancer that has stopped responding to or cannot tolerate initial treatment. It aims to see if the combination can shrink tumors or slow the disease.
This trial tests a new drug called LM-108 combined with chemotherapy for people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if it's safe and may help shrink tumors or stop them from growing.
This trial tests if adding leflunomide (a drug used for arthritis) to standard chemotherapy (gemcitabine) can help people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the combination works better than gemcitabine alone.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.